Other equities analysts have also recently issued research reports about the stock. Cormark cut shares of Spectral Medical from a buy rating to a reduce rating in a research note on Monday. GMP Securities reaffirmed a speculative buy rating on shares of Spectral Medical in a research note on Wednesday, September 14th.
Spectral Medical (TSE:EDT) opened at 0.215 on Monday. The firm’s market cap is $44.45 million. The company’s 50-day moving average is $1.22 and its 200 day moving average is $1.02. Spectral Medical has a 12 month low of $0.18 and a 12 month high of $2.07.
Spectral Medical Company Profile
Spectral Medical Inc, formerly Spectral Diagnostics Inc, is a therapeutic development company. The Company is focused on the development and commercialization of a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) and the Toraymyxin (PMX) therapeutic. The Company also manufactures and sells certain reagents.
Receive News & Ratings for Spectral Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Medical Inc and related companies with MarketBeat.com's FREE daily email newsletter.